TAK-003疫苗在巴西圣保罗2024年登革热暴发中对青少年的有效性:检测阴性病例对照研究
该研究采用检测阴性病例对照设计,在2024年巴西圣保罗州10-14岁青少年中评估TAK-003登革热疫苗的实际有效性。
核心结论
- TAK-003在主要由登革病毒1型和2型引起的大暴发中,对青少年症状性登革热和住院均有效。
研究设计与样本
- 检测阴性病例对照研究,纳入巴西圣保罗州10-14岁青少年,2024年2月20日至12月31日。
- 病例为急性发热且NS1抗原或RT-PCR确诊登革热者,对照为急性发热但登革热检测阴性者,检测均在症状出现5天内完成。
- 共纳入92 621例检测结果,其中病例43 873例,对照48 748例。
- 数据来自国家登革热监测数据库和圣保罗州卫生厅疫苗接种登记。
- 采用混合效应逻辑回归模型估计疫苗有效性。
主要发现
- 敏感性分析显示结果稳健,但第二剂估计受事件数少限制。
临床怎么用
- 在登革热高传播地区及应急响应中,TAK-003可用于青少年接种以预防症状性登革热和住院。
- 首剂后早期保护较高但90天后下降,需关注后续剂次和持续保护。
局限性
- 第二剂有效性估计受观察事件数少限制。
- 研究仅纳入10-14岁青少年,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dengue is a substantial public health challenge in tropical regions, and is considered a global health threat owing to its expanding geographical range and increasing incidence as a result of climate change. Despite the availability of tetravalent dengue vaccines, real-world evidence on their effectiveness is scarce. We aimed to evaluate the vaccine effectiveness of the dengue vaccine TAK-003 in adolescents during the 2024 dengue outbreak in the state of São Paulo, Brazil. METHODS: This test-negative, case-control study was conducted among adolescents aged 10-14 years in São Paulo state, Brazil, from Feb 20 to Dec 31, 2024. Cases were defined as individuals with acute febrile illness and virologically confirmed dengue, and controls as individuals with acute febrile illness who tested negative for dengue; in both groups, confirmation was based on NS1 antigen or RT-PCR testing within 5 days of symptom onset. Data were obtained from the national surveillance databases for dengue and the São Paulo State Secretary of Health vaccination registry. We used mixed-effects logistic regression models to estimate vaccine effectiveness against symptomatic, virologically confirmed dengue and against hospitalisation with dengue after one or two doses of the vaccine. FINDINGS: Of 128 358 potentially eligible tests, 92 621 were included in the analysis: 43 873 from cases and 48 748 from controls. Adjusted vaccine effectiveness was 50·2% (95% CI 45·0-54·9) for the first dose and 61·7% (39·9-75·6) for the second dose against symptomatic dengue, and 67·5% (95% CI 43·4-81·3) for the first dose against hospitalisation with dengue. Protection against symptomatic disease began 14 days after the first dose (67·4% [57·2-75·1] at 14-27 days), but declined to 49·7% (30·4-63·6) after 90 days from the first dose. Sensitivity analyses showed the robustness of these findings, although estimates for the second dose were limited by the small number of events observed. INTERPRETATION: TAK-003 was effective against symptomatic dengue and hospitalisation with dengue in adolescents during a large outbreak caused predominantly by dengue virus serotypes 1 and 2. These findings underscore the importance of real-world evidence in guiding dengue vaccination strategies, particularly in high-transmission settings and during emergency response use. FUNDING: National Council for Scientific and Technological Development. TRANSLATION: For the Portuguese translation of the abstract see Supplementary Materials section.
引用
- Ranzani OT, Lazar Neto F, Mareto LK, et al. Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case-control study. Lancet Infect Dis. 2025. PMID: 40845862. doi:10.1016/S1473-3099(25)00382-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。